OpenEvidence Secures $250M To Guide Evidence-Based Decision Making
MobiHealthNews
|
Contributed by: Kate Gamble
Summary
OpenEvidence, an AI-driven medical research platform, has secured $250 million in Series D funding, raising its valuation to $12 billion and totaling nearly $700 million in funding over the past year. Led by Thrive Capital and DST Global, this investment will enable OpenEvidence to enhance its platform, which helps healthcare professionals make evidence-based decisions by synthesizing clinical information from multiple sources. Collaborations with prestigious medical organizations underscore the platform’s role in keeping doctors informed of the latest research, potentially improving patient care by streamlining access to critical findings. This significant financial boost highlights the growing integration of AI in healthcare, emphasizing the demand for technology that supports informed clinical decision-making.
